Table 3.
Summary of meropenem clinical efficacy trials in complicated skin and soft tissue infections
| Response | |||||||
|---|---|---|---|---|---|---|---|
| Reference | Study type | Evaluable patients (N) | Regimen | Mean duration of therapy (days) | Clinical (%) | Bacteriologic (%) | Drug-related AE (%) |
| Lami et al 1991 | P, R, NB | 23 | M 500 mg q8h | 6.4 | 100 | NR | NR |
| 21 | I/C 500 mg q6h | 6.5 | 100 | NR | NR | ||
| Nichols et al 1995 | P, R, MC, NB | 123 | M 500 mg q8h | 7.1 | 98 | 94 | 14 |
| 126 | I/C 500 mg q6h | 7.3 | 95 | 91 | 16 | ||
| Fabian et al 2005 | P, R, MC, DB | 261 | M 500 mg q8h | 5.8 a | 86.2 | 88.5 | 9.0 |
| 287 | I/C 500 mg q8h | 6.0 a | 82.9 | 83.1 | 10.8 | ||
a
Note: aNumbers in table represent duration of parenteral therapy only. Approximately 50% of patients in each treatment group were switched to oral therapy and treated for an additional mean of 9.3 and 9.0 days in meropenem and I/C groups, respectively.
Abbreviations: AE, adverse events; DB, double-blind; I/C, imipenem/cilastatin; M, meropenem; MC, multicentered; NB, non-blinded; NR, not reported; P, prospective; R, randomized.